Illumina Officials Say Array Business Will Benefit from Epicentre Buy
February 15, 2011
Illumina Officials Say Array Business Will Benefit from Epicentre Buy
CEO Jay Flatley said Illumina has in the past licensed "several" Epicentre enzymes for use in its array business. Now the company has the "ability to use those enzymes at cost rather than [retail] price."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.